Chronic Lower Back Pain
2
Pipeline Programs
4
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
BRIXADIApproved
buprenorphine
Braeburn PharmaceuticalsPartial Opioid Agonist [EPC]subcutaneous2023
363K Part D
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Medpacebuprenorphine
Aspen Medical productsLumbar Brace
Clinical Trials (2)
Total enrollment: 1,089 patients across 2 trials
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
Start: Sep 2016Est. completion: Feb 20191,053 patients
Phase 3Completed
Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention
Start: Jan 2015Est. completion: Dec 201636 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.